[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:lung-non-small-cell-carcinoma:erbb2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Lung Non-Small Cell Carcinoma","ERBB2 Gene",20,[8,16,22,29,36,42,49,55,61,67,73,79,85,91,97,103,109,115,121,127],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06043817","First-In-Human Study of STX-721\u002FPFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:55.355429Z","2026-05-05T02:43:29.021992Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07012031","Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation",[12],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:28.418568Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06745908","Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In",[26],"Phase 3","2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.120702Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05681780","Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC",[33],"Phase 1","2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.992106Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07195695","Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment",[26],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:27.661184Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT07428044","A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer",[46],"Phase 2","2026-08-26T02:16:36.513735Z","2026-05-05T02:43:27.588648Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06521554","A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)",[33],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:26.963151Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06616766","A Phase 1\u002F2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946",[12],"2026-08-26T02:18:15.214990Z","2026-05-05T02:35:31.680026Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06706076","A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and\u002For HER2 Mutations",[12],"2026-08-26T02:19:02.550788Z","2026-05-05T02:35:31.637829Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",[12],"2026-08-26T02:15:39.267524Z","2026-04-29T02:57:57.062678Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05315700","Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration",[12],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.704037Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06804824","A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors",[33],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.192980Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07361562","A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors",[33],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.101090Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05872295","IKS014 in Advanced Solid Tumors That Express HER2",[33],"2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.816198Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05150691","A Phase 1\u002F2a Study of DB-1303\u002FBNT323 in Advanced\u002FMetastatic Solid Tumors",[12],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.396080Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06695845","A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",[46],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.744064Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[12],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06253871","A Phase 1\u002F1b Study of IAM1363 in HER2 Cancers",[33],"2026-08-26T02:18:31.944757Z","2026-05-05T02:35:31.700916Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT05099172","First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and\u002For Human Epidermal Growth Factor Receptor 2 (HER2)",[12],"2026-08-26T02:19:28.327680Z","2026-06-14T18:39:22.231084Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT05236114","GEMINI-NSCLC: NSCLC Biomarker Study",[],"2026-08-26T02:17:44.240289Z","2026-05-13T02:55:06.297367Z"]